

# The Institute for Clinical and Economic Review



**The Institute for Clinical and Economic Review (ICER) is a nonprofit that conducts research on how well prescription drugs and other treatments work for patients and what a fair price should be.**

# ICER's Work

ICER conducts health technology assessments (HTA) - a research process that evaluates how much added benefit a new treatment brings to patients when compared to existing options.

## ICER's Goal

ICER wants the price of treatments to match the benefits that patients and families receive. Treatments that work really well should cost more, while treatments that don't work as well, should cost less. Treatments that are fairly priced should be easy for patients to access.

## ICER's Public Process

To do this, ICER works with patient groups, patients and caregivers, clinicians, insurers, and manufacturers to understand the added benefit of the new treatment. Our work is transparent and publicly available on our website, [icer.org](https://icer.org).

## ICER's Independent Funding

To remain independent, ICER receives the majority of our funding from nonprofit foundations to ensure that our research is free from conflicts of interest. We list all our sources of funding [here](#).



# Impact of ICER's Work

**While ICER has no regulatory power, our reports are freely available for public use. ICER's recommendations help inform decision makers on how to think about fair pricing and fair access to a new treatment.**



**Patient groups** can use the ICER report as an evidence-based tool to advocate for fair pricing and access.



**Private payers and employer groups** can use the ICER report to better understand the patient lived experience, negotiate fairer prices, and guide coverage policy.



**State Medicaid programs and Veterans Affairs (VA)** can use the ICER report to negotiate for rebates and expand patient access.



**Manufacturers** can use the ICER report to inform decisions around pricing and access for their product.

# Why Does ICER's Work Matter?

## PROBLEM

When we overpay for a treatment, there's a **direct consequence for everyone** in the US health system (rising insurance premiums, unaffordable insurance coverage, worse health outcomes). **When we underpay for a treatment, we may discourage future innovation.**

## OPPORTUNITY

ICER invites the **patient community to participate** in the review process to ensure that the **priorities of patients and families are reflected** in how a fair price is calculated for a new treatment.

## SOLUTION

ICER reports provide **evidence to decision makers on how to price treatments fairly** based on how safe and effective they are for patients.

**ICER is working toward a health care system that can provide all patients access to the treatments they need at prices everyone can afford.**